ChemoCentryx - CCXI Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChemoCentryx in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CCXI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CCXI, but not buy additional shares or sell existing shares.
View CCXI analyst ratings or view top-rated stocks.

5 analysts have issued 12 month price objectives for ChemoCentryx's shares. Their CCXI share price forecasts range from $52.00 to $81.00. On average, they predict the company's stock price to reach $59.25 in the next year. This suggests a possible upside of 14.0% from the stock's current price.
View analysts price targets for CCXI or view top-rated stocks among Wall Street analysts.

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. The biopharmaceutical company had revenue of $17.74 million for the quarter, compared to analysts' expectations of $14.70 million. ChemoCentryx had a negative net margin of 357.01% and a negative trailing twelve-month return on equity of 48.52%. During the same period last year, the business earned ($0.35) EPS.

21 employees have rated ChemoCentryx Chief Executive Officer Thomas J. Schall on Glassdoor.com. Thomas J. Schall has an approval rating of 58% among the company's employees. This puts Thomas J. Schall in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 44.0% of employees surveyed would recommend working at ChemoCentryx to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other ChemoCentryx investors own include Exelixis (EXEL), Energy Transfer (ET), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Advanced Micro Devices (AMD) and Arrowhead Pharmaceuticals (ARWR).

ChemoCentryx trades on the NASDAQ under the ticker symbol "CCXI."

ChemoCentryx's stock is owned by many different retail and institutional investors. Top institutional investors include Jane Street Group LLC (0.00%), Centiva Capital LP (0.00%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%), Cutler Group LLC CA (0.00%) and Equitec Proprietary Markets LLC (0.00%). Insiders that own company stock include (International) Ltd Vifor, Geoffrey M Parker, James L Tyree, Markus J Cappel, Pui San Kwan, Susan M Kanaya, Tausif Butt, Thomas A Edwards and Thomas J Schall.
View institutional ownership trends.

One share of CCXI stock can currently be purchased for approximately $51.99.

ChemoCentryx (NASDAQ:CCXI) has a market capitalization of $3.71 billion and generates $32.22 million in revenue each year. The biopharmaceutical company earns $-131,760,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis.

The company employs 178 workers across the globe.

ChemoCentryx's mailing address is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. The official website for the company is www.chemocentryx.com. The biopharmaceutical company can be reached via phone at (650) 210-2900, via email at investor@chemocentryx.com, or via fax at 650-210-2910.